DE10032608A1 - Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte - Google Patents
Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre GenprodukteInfo
- Publication number
- DE10032608A1 DE10032608A1 DE10032608A DE10032608A DE10032608A1 DE 10032608 A1 DE10032608 A1 DE 10032608A1 DE 10032608 A DE10032608 A DE 10032608A DE 10032608 A DE10032608 A DE 10032608A DE 10032608 A1 DE10032608 A1 DE 10032608A1
- Authority
- DE
- Germany
- Prior art keywords
- msi
- genes
- cells
- cmnr
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 135
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 63
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- 230000035772 mutation Effects 0.000 claims abstract description 31
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 29
- 108091092878 Microsatellite Proteins 0.000 claims abstract description 22
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000003053 immunization Effects 0.000 claims description 6
- 238000002649 immunization Methods 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000007479 molecular analysis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 72
- 239000000047 product Substances 0.000 description 41
- 238000004458 analytical method Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 208000037051 Chromosomal Instability Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000057361 Pseudogenes Human genes 0.000 description 3
- 108091008109 Pseudogenes Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000615492 Homo sapiens Methyl-CpG-binding domain protein 4 Proteins 0.000 description 2
- 101000643620 Homo sapiens Synaptonemal complex protein 1 Proteins 0.000 description 2
- 101000631620 Homo sapiens Translocation protein SEC63 homolog Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100021290 Methyl-CpG-binding domain protein 4 Human genes 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 102100029006 Translocation protein SEC63 homolog Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 101150010487 are gene Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241001160050 Bat mastadenovirus Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 1
- 101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091035233 repetitive DNA sequence Proteins 0.000 description 1
- 102000053632 repetitive DNA sequence Human genes 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10032608A DE10032608A1 (de) | 2000-07-07 | 2000-07-07 | Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte |
| US10/332,522 US20040265803A1 (en) | 2000-07-07 | 2001-07-04 | Genes and their genetic products pertinent to microsatellite instable (msi+) tumours |
| AU2001281708A AU2001281708A1 (en) | 2000-07-07 | 2001-07-04 | Genes comprising coding mononucleotide microsatellites or dinucleotide microsatellites that can be isolated from tumour cells |
| PCT/DE2001/002510 WO2002004664A2 (de) | 2000-07-07 | 2001-07-04 | Aus tumorzellen isolierbare gene mit kodierenden mononucleotid- oder dinucleotid-mikrosatelliten |
| JP2002509517A JP2004512021A (ja) | 2000-07-07 | 2001-07-04 | ミクロサテライト不安定（ｍｓｉ＋）腫瘍に適切な遺伝子およびその遺伝子産物 |
| EP01960106A EP1352088A2 (de) | 2000-07-07 | 2001-07-04 | Aus tumorzellen isolierbare gene mit kodierenden mononucleotid- oder dinucleotid-mikrosatelliten |
| CA002415199A CA2415199A1 (en) | 2000-07-07 | 2001-07-04 | Genes and their genetic products pertinent to microsatellite instable (msi+) tumours |
| NO20030052A NO20030052L (no) | 2000-07-07 | 2003-01-06 | Gener og deres genprodukter relevante for mikrosatelitt ustabile (MSI+)tumorer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10032608A DE10032608A1 (de) | 2000-07-07 | 2000-07-07 | Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10032608A1 true DE10032608A1 (de) | 2002-01-24 |
Family
ID=7647836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10032608A Withdrawn DE10032608A1 (de) | 2000-07-07 | 2000-07-07 | Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040265803A1 (https=) |
| EP (1) | EP1352088A2 (https=) |
| JP (1) | JP2004512021A (https=) |
| AU (1) | AU2001281708A1 (https=) |
| CA (1) | CA2415199A1 (https=) |
| DE (1) | DE10032608A1 (https=) |
| NO (1) | NO20030052L (https=) |
| WO (1) | WO2002004664A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361286A1 (en) * | 2002-04-18 | 2003-11-12 | MTM Laboratories AG | Method for detection of cancer |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003232485A1 (en) | 2002-04-18 | 2003-10-27 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| EP1354895A1 (en) * | 2002-04-18 | 2003-10-22 | MTM Laboratories AG | Neopeptides useful for detection and treatment of cancer |
| CA2651796A1 (en) * | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| US9732131B2 (en) * | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
| AU744157B2 (en) * | 1997-07-28 | 2002-02-14 | Fox Chase Cancer Center | Novel gene encoding a DNA repair endonuclease and methods of use thereof |
| CA2417866A1 (en) * | 2000-08-03 | 2002-02-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
-
2000
- 2000-07-07 DE DE10032608A patent/DE10032608A1/de not_active Withdrawn
-
2001
- 2001-07-04 JP JP2002509517A patent/JP2004512021A/ja active Pending
- 2001-07-04 US US10/332,522 patent/US20040265803A1/en not_active Abandoned
- 2001-07-04 EP EP01960106A patent/EP1352088A2/de not_active Withdrawn
- 2001-07-04 WO PCT/DE2001/002510 patent/WO2002004664A2/de not_active Ceased
- 2001-07-04 CA CA002415199A patent/CA2415199A1/en not_active Abandoned
- 2001-07-04 AU AU2001281708A patent/AU2001281708A1/en not_active Abandoned
-
2003
- 2003-01-06 NO NO20030052A patent/NO20030052L/no unknown
Non-Patent Citations (1)
| Title |
|---|
| Nucleic Acids Res 25, 1997, S. 806-813 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361286A1 (en) * | 2002-04-18 | 2003-11-12 | MTM Laboratories AG | Method for detection of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| NO20030052D0 (no) | 2003-01-06 |
| WO2002004664A3 (de) | 2003-06-19 |
| AU2001281708A1 (en) | 2002-01-21 |
| WO2002004664A2 (de) | 2002-01-17 |
| NO20030052L (no) | 2003-03-07 |
| JP2004512021A (ja) | 2004-04-22 |
| CA2415199A1 (en) | 2003-01-07 |
| US20040265803A1 (en) | 2004-12-30 |
| WO2002004664A9 (de) | 2002-09-19 |
| EP1352088A2 (de) | 2003-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126592T2 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
| DE69933998T2 (de) | Verbindungen und verfahren für therapie und diagnose von lungenkrebs | |
| Shimonkevitz et al. | Transient expression of IL-2 receptor precedes the differentiation of immature thymocytes | |
| DE69526339T2 (de) | Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide | |
| DE69433518T2 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
| EP1508047B1 (de) | Verfahren zur identifizierung von immunreaktiven peptiden | |
| DE69333670T2 (de) | Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen | |
| DE60019273T2 (de) | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung | |
| DE3752360T2 (de) | Menschliche DNS zum Nachweis von Retinoblastoma | |
| Norris et al. | Oligoclonal expansion of intraepidermal T cells in psoriasis skin lesions | |
| DE69707985T2 (de) | Kodierende sequenzen des menschlichen brca1-gens | |
| JPH11308993A (ja) | ｃＤＮＡライブラリーの作製方法およびポリペプチドのスクリーニング方法 | |
| EP2314610B1 (de) | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung | |
| DE69534624T2 (de) | Transkripte des HLA-G-Gens des Haupthistokompatibilitätskomplexes (MHC)-Klasse 1 und ihre Anwendungen | |
| DE10032608A1 (de) | Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte | |
| Kaminski et al. | Acetylcholine receptor subunit gene expression in thymic tissue | |
| Morita et al. | JH8, a Gene Highly Homologous to the MousejerkyGene, Maps to the Region for Childhood Absence Epilepsy on 8q24 | |
| DE69829587T2 (de) | Nukleinsäuremoleküle, die mit dem schwachen rhesus-d phänotyp korrelieren | |
| DE60217651T2 (de) | Zur modulation der krebszellenproliferation geeignetes polynukleotid | |
| EP1007671B1 (de) | Fanconi-gen ii | |
| DE69616288T2 (de) | Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6 | |
| DE102015106731A1 (de) | Peptide für die Krebsimmuntherapie | |
| DE19849044A1 (de) | Das Gen PRV-1 und dessen Verwendung | |
| EP0991780A2 (de) | Verfahren und testkit zum nachweis bösartiger tumore | |
| EP1301624A2 (en) | Preprocalcitonin as tumor rejection antigen precursor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |